



Icatibant

Catalog No: tcsc3381

Available Sizes
Size: 1mg
Size: 5mg
Size: 10mg
Specifications
CAS No: .30308-48-4
Formula: C ₅₉ H ₈₉ N ₁₉ O ₁₃ S
Pathway: GPCR/G Protein
Target: Bradykinin Receptor
Purity / Grade: >98%
Solubility: .0 mM in DMSO
Alternative Names: HOE 140
Observed Molecular Weight: .304.52

Product Description





Icatibant(HOE-140) is a selective and specific antagonist of bradykinin B2 receptor with IC50 and Ki of 1.07 nM and 0.798 nM respectively.

IC50 value: 1.07 nM [1]

Target: bradykinin B2 receptor antgonist

in vitro: In receptor binding studies in guinea-pig ileum preparations, Hoe 140 showed an IC50 of 1.07 x 10(-9) mol l-1 and a KI value of 7.98 x 10(-10) mol l-1. In isolated organ preparations Hoe 140 and D-Arg-[Hyp2,Thi5,8, D-Phe7]BK inhibited bradykinin-induced contractions concentration dependently, with IC50-values in the guinea-pig ileum preparation of $1.1 \times 10(-8)$ mol l-1 and $3 \times 10(-5)$ mol l-1, respectively. pA2 values in this tissue were 8.42 and 6.18, respectively [1].

in vivo: HOE 140 (1, 3, or 10 μ g/10 μ l physiological saline) was administered into the wound by a sterile micropipette. HOE 140 (1, 3, 10 μ g) significantly relieved mechanical allodynia and guarding in comparison with vehicle-treated group [2]. HOE-140 (10 nmol/kg) protected against memory impairment. This treatment attenuated the brain edema, interleukin-1 β , tumor necrosis factor- α , and nitric oxide metabolites content elicited by mLFPI. Accordingly, HOE-140 administration protected against the increase of nicotinamide adenine dinucleotide phosphate oxidase activity, thiobarbituric-acid-reactive species, protein carbonylation generation, and Na+ K+ ATPase inhibition induced by trauma [3].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!